Clinical trials of Abciximab

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
Abciximab + reteplase vs primary intervention			
BRAVE (Kastrati) , 2004 n=125/128 follow-up: 30 days	-	symptom duration <12h	
FINESSE (combination-facilitated PCI) , 2008 [NCT00046228] n=828/806 follow-up: 90 days	combination-facilitated PCI with abciximab plus half-dose reteplase versus primary PCI (abciximab administered immediately before the procedure)	patients with acute ST-segment elevation myocardial infarction; symptom duration <6h	Parallel groups open
Abciximab vs primary intervention			
ERAMI (Mesquita Gabriel) , 2003 n=36/38 follow-up: 30-day	facilated PCI with Abciximab; 025 mg/kg intravenous bolus, 0125 g/kg per min infusion versus primary intervention	symptom duration <12h	
FINESSE (abciximab-facilitated PCI) , 2008 [NCT00046228] n=818/806 follow-up: 90 days	abciximab-facilitated PCI versus primary PCI (abciximab administered immediately before the procedure)	patients with acute ST-segment elevation myocardial infarction; symptom duration <6h	Parallel groups open
REOMOBILE (Arntz) , 2003 n=52/48 follow-up: 30-day	facilated PCI with Abciximab; 025 mg/kg intravenous bolus, 0125 g/kg per min infusion versus primary intervention	symptom duration <6h	
Zorman , 2002 n=56/56 follow-up: In hospital	facilated PCI with Abciximab; 025 mg/kg intravenous bolus, 0125 g/kg per min infusion versus primary intervention	symptom duration <12h	

Trial	Treatments	Patients	Trials design and methods
ReoPro-BRIDGING (Gyongyosi) , 2004 n=28/27 follow-up: 30-day	facilated PCI with Abciximab; 025 mg/kg intravenous bolus, 0125 g/kg per min infusion versus primary intervention	symptom duration <6h	
Bellandi , 2006 n=27/28 follow-up: 30-day	facilated PCI with Abciximab; 025 mg/kg intravenous bolus, 0125 g/kg per min infusion versus primary intervention	symptom duration <6h	

More details and results :

- myocardial revascularization for acute myocardial infarction in facilated PCI at http://www.trialresultscenter.org/go-Q90

References

BRAVE (Kastrati), 2004:

Kastrati A, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, Nekolla SG, Seyfarth M, Martinoff S, Markwardt C, Clermont G, Gerbig HW, Leiss J, Schwaiger M, Schmig A Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 2004;291:947-54 [14982910]

FINESSE (combination-facilitated PCI), 2008:

Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neum Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008 May 22;358:2205-17 [18499565]

ERAMI (Mesquita Gabriel), 2003:

Mesquita Gabriel H, Oliveira J, et almag Early administration of abciximab bolus in the emergency room improves microperfusion after primary percutaneous coronary intervention, as assessed by TIMI frame count: results of the ERAMI trialNO Eur Heart J 2003; 24 (suppl): 543 (abstrtxtPag

FINESSE (abciximab-facilitated PCI), 2008:

Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neum Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008 May 22;358:2205-17 [18499565]

REOMOBILE (Arntz), 2003:

Arntz HR, Schroeder J, Pels K, Schwimmbeck P, Witzenbichler B, Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE study=132 Eur Heart J 2003; 24 (suppl): 268 (abstr).xtPag

Zorman, 2002:

Zorman S, Zorman D, Noc M Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002;90:533-6 [12208418]

ReoPro-BRIDGING (Gyongyosi), 2004:

Gyngysi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, Hdl R, Gaul G, Bonner G, Wojta J, Laggner A, Glogar D, Huber K Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J 2004;25:2125-33 [15571828]

Bellandi, 2006:

Bellandi F, Maioli M, Leoncini M, Toso A, Dabizzi RP Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Int J Cardiol 2006;108:36-42 [15927285]

2 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
abciximab-coated stent vs bare-metal stent			
Kim , 2010 n=93 follow-up: 6 mo (2y)	abciximab-coated stent versus bare metal stents	patients undergoing PCI for de novo coronary lesions	Parallel groups open Korea

More details and results :

- myocardial revascularization for coronary artery disease in all type of patient at http://www.trialresultscenter.org/go-Q26

- Drug eluting stent for coronary artery disease in all type of patients at http://www.trialresultscenter.org/go-Q206

References

Kim, 2010:

Kim SS, Hong YJ, Jeong MH, Kim W, Kim HK, Ko JS, Lee MG, Sim DS, Park KH, Yoon NS, Yoon HJ, Kim KH, Park HW, Kim JH, Ahn Y, Cho JG, Park JC, Song SJ, Cho DL, Kang JC Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease. Circ J 2010;74:442-8 [20103970]

3 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
Abciximab vs placebo			

Trial	Treatments	Patients	Trials design and methods
ADMIRAL , 2001 n=NA	-	Primary PCI	
CADILLAC , 2002 n=NA	-	Primary PCI	
RAPPORT , 1998 n=NA	-	Primary PTCA <	
EPIC (with infusion) , 1994 n=NA	-	High risk for abrupt closurebitm	
EPILOG , 1997 n=NA	-	Elective or urgent PCIe	
EPISTENT , 1998 n=NA	-	Elective or urgent PCI	
CAPTURE , 1997 n=NA	-	-	
ERASER , 1999 n=NA	-	-	
Petronio , 2002 n=NA	-	-	
Simoons , 1994 n=NA	-	-	
Kini , 2001 n=NA	-	-	
Tamburino , 2002 n=NA	-	-	
ISAR-2 , 2000 n=NA	-	PCI <48 h after MI	
enoxaparin+abciximab vs UFH			
Dubek b (+abciximal) , 2001 n=NA	Enoxaparin 0.75 mg/kg bolus + abciximab versus UFH titrated to ACT >300	-	

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at http://www.trialresultscenter.org/go-Q63

- anticoagulant for percutaneous coronary intervention in all type of patients at http://www.trialresultscenter.org/go-Q388

References

ADMIRAL, 2001:

Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiri M, Choussat R, Pinton P Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903 [11419426]

CADILLAC, 2002:

Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66 [11919304]

RAPPORT, 1998:

Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-41 [9727542]

EPIC (with infusion), 1994:

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61 [8121459]

Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343:881-6 [7908357]

Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479-84 [9256222]

EPILOG, 1997:

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96 [9182212]

EPISTENT, 1998:

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92 [9672272]

Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999;341:319-27 [10423466]

Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999;354:2019-24 [10636365]

CAPTURE, 1997:

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35 [9164316]

ERASER, 1999:

Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. Circulation 1999;100:799-806 [10458714]

Petronio, 2002:

Petronio AS, Musumeci G, Limbruno U, De Carlo M, Baglini R, Paterni G, Grazia Delle Donne M, Caravelli P, Nardi C, Mariani M Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J 2002;143:334-41 [11835040]

Simoons, 1994:

Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Circulation 1994;89:596-603 [7508826]

Kini, 2001:

Kini A, Reich D, Marmur JD, Mitre CA, Sharma SK Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial. Am Heart J 2001;142:965-9 [11717598]

Tamburino, 2002:

Tamburino C, Russo G, Nicosia A, Galassi AR, Foti R, Scriffignano V, Kereiakes DJ, Giuffrida G Prophylactic abciximab in elective coronary stenting: results of a randomized trial. J Invasive Cardiol 2002;14:72-9 [11818641]

ISAR-2, 2000:

Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schleef M, Seyfarth M, Dirschinger J, Schmig A Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21 [10732888]

Dubek b (+abciximal), 2001:

Entry terms: enoxaparin, Lovenox, Clexane, abciximab